QDEL
QuidelOrtho Corporation
Healthcare · Medical Devices · NMS
$14.33
Data: 2026-05-28
✓ ETHICAL PASS

Unknown MOAT
HIGH
Data Confidence: 85.7%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$841M
Total market value of the company
5.05
Based on estimated future earnings — lower means cheaper
Rev Growth
-10.5%
Year-over-year revenue change
Profit Margin
-45.6%
How much profit the company keeps from each dollar of revenue
-49.9%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$12.75
-11% from current price — median analyst estimate
Recommendation
HOLD
Consensus view from 4 analysts covering this stock
About QuidelOrtho Corporation

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

https://www.quidelortho.com

Country: United States Employees: 6,500 Industry: Medical Devices
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% N/A
Debt must be below 33% of total assets
Cash Ratio
0.0% N/A
Interest-bearing cash below 33% of assets
Receivables
0.0% N/A
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

MARKUP
Price trending up with increasing momentum
-0.504
Returns do not compensate for the risk — negative edge
-0.0556
No positive edge detected — the data suggests staying out
-0.576
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-45.5%
Historical annualised return based on price data
-79.1%
Largest peak-to-trough decline — the worst it has been
BEAR
Statistical model detects bearish conditions
Days in State
29
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

0.74
Less volatile than the market — more defensive
52W High
$35.58
60% below the year high
52W Low
$9.92
44% above the year low
Avg Volume
2,277,000
Average daily shares traded — higher means easier to buy and sell
3.8
Days it would take all short sellers to cover — higher means more crowded
Short % Float
23.6%
Very high short interest — potential squeeze candidate
N/A
Annual dividend as a percentage of the share price
$-17.85
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

155.27
Heavy leverage — higher financial risk if revenues decline
1.43
Adequate but worth monitoring
Quick Ratio
0.65
Like current ratio but excludes inventory — stricter test
Gross Margin
45.2%
Revenue left after cost of goods — higher means pricing power
Operating Margin
-4.1%
Profit from core operations before interest and tax
$209M
Positive — the business generates more cash than it spends
Revenue (TTM)
$2.7B
Total revenue over the last 12 months
Net Income
$-1,210,899,968
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
4
Target High
$38.00
Target Median
$12.75
Target Low
$11.00
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.